clinicaltrialsarena

Veradermics’ stock up on male hair loss trial success

The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair ...
clinicaltrialsarena

FDA clears Caliway’s trial of CBL-514 for localised fat reduction

Recruitment for the trial is set to commence in the third quarter of this year. Credit: Johnstocker Production / Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Caliway ...
clinicaltrialsarena

Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC

Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small ...
clinicaltrialsarena

BMS gains two pivotal trial wins in lung disease and rare cancer

BMS announced data from two pivotal trials, with both showing success. Credit: PixelBiss / Shutterstock.com Bristol Myers Squibb (BMS) has seen success in two pivotal trials, one in idiopathic ...
clinicaltrialsarena

Cerevance’s novel Parkinson’s drug nets a Phase III win

Cerevance will now speak with the FDA about next steps for solengrapas in Parkinson’s disease. Credit: PeopleImages / Shutterstock.com. Boston-based biotech Cerevance’s first-in-class Parkinson’s ...
clinicaltrialsarena

Lilly reports Phase IIIb data on Taltz and Zepbound combination

The trial randomised 274 participants to subcutaneous Taltz or the combination, alongside counselling on diet and physical activity. Credit: Pixel-Shot/Shutterstock.com. Eli Lilly and Company has ...
clinicaltrialsarena

Argenx’s Vyvgart shows durability in myositis and Sjögren’s

argenx is already running Phase III trials of Vyvgart in both myositis and Sjögren’s. Credit: Sheldon Cooper/SOPA Images/LightRocket via Getty Images Argenx’s Vyvgart (efgartigimod alfa-fcab) shows ...
clinicaltrialsarena

Tortugas’ Phase IIb schizophrenia trial of obuprazine meets primary endpoint

Obuprazine functions as a dopamine D2/D3 receptor partial agonist, a 5-HT1A receptor partial agonist, and a 5-HT2A receptor antagonist. Credit: Antonio Marca/Shutterstock.com. Tortugas Neuroscience ...
clinicaltrialsarena

Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033

A major focus of R&D in the Alzheimer’s disease therapeutic space is preventing the accumulation of amyloid beta.
clinicaltrialsarena

Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial

Arrowhead announced the Phase I/IIa data for its RNAi therapy. Credit: Antonio Marca / Shutterstock.com Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for ...
clinicaltrialsarena

AstraZeneca pins bone disease drug’s Phase III failure on high placebo response

Efzimfotase alfa offered numerical, but not statistically significant improvements in patient six-minute walk test values in the HICKORY trial in hypophosphatasia. Credit: Lemberg Vector studio / ...
clinicaltrialsarena

Mirum tees up Livmarli label expansion on Phase III liver disease study success

Mirum plans to file a sNDA for Livmarli in the first half 0f 2027. Credit: Vectomart / Shutterstock.com. Mirum Pharmaceuticals’ marketed therapy, Livmarli (maralixibat), could be poised for a label ...